Terrorism and other mass casualty events have been the mother of invention for the Hadassah Medical Center’s orthopedic trauma teams.
The Hadassah Medical Center, using the powerful research tool of advanced gene sequencing, has identified a gene mutation that 3 of a couple’s 12 children shared, which caused them to have an intellectual disability, short stature, seizures, and disturbed glucose metabolism. Now the other healthy children are able to be tested to see if they carry the mutation and to plan their futures.
“He was two and a half months old when I saw him for the first time,” said Hadassah Medical Center Pediatric Ophthalmologist Dr. Irene Anteby about the East Jerusalem baby who was assumed to be blind. Dr. Anteby, however, realized he wasn’t reacting to light because dense cataracts were blocking his vision.
“Today we are seeing a revolution in the treatment of melanoma and the Hadassah Medical Center is among the world leaders because we always believed that the immune system can combat cancer,” says Dr. Michal Lotem, head of Hadassah’s Center for Melanoma and Cancer Immunotherapy.
The terrorist is placed in the far left bay; the man he’d stabbed is to the right.
How many times have I explained that we treat Jew and Arab, even terror victim and terrorist, exactly the same?
On November 5, 2014 there was a possible terror attack by car that hit IDF soldiers in Gush Etzion. Three were sent to our hospital in Ein Kerem.
On October 22, 2014 a Hamas supporter drove into a crowd waiting to ride Jerusalem's light rail, killing a baby and seriously injuring a woman traveler who later died at Hadassah Ein Kerem.
November 4, 2014 a second act of terror killed and wounded people waiting for the light train.
Active and independent, doing her own shopping and cooking along with volunteer work in the West Bank city of Bethlehem, Maria, age 82, suddenly collapsed after she stopped taking her blood thinner to prepare for a dental procedure.
Describing the Hadassah Medical Center’s new inpatient facility-- the Sarah Wetsman Davidson Hospital Tower--as “a beacon of healing that rises from the Jerusalem hillside,” Acting Director General Prof. Tamar Peretz explained to her New York audience of supporters that “a steering committee of people on both sides of the ocean worked together to plan the best hospital building in the world.”
Jerusalem’s Cell Cure Neurosciences, whose mission is to become a leading supplier of human cell-based therapies for the treatment of retinal and neurodegenerative diseases, has received approval from the United States Food and Drug Administration (FDA) to conduct a clinical trial to treat the dry form of age-related macular degeneration (AMD) with OpRegen®, a first-of-its kind animal product-free, retinal pigment epithelial (RPE) cell formulation derived from human embryonic stem cells (hESCs).